Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Esperion Therapeutis.Inc.

Start price
Target price
Perf. (%)
€4.62
03.12.21
-
03.12.22
0.84%
11.12.21

Could be worthwhile Investment >10% per year
buy
Radius Health Inc.

Start price
Target price
Perf. (%)
€13.05
05.12.21
-
05.12.22
-48.66%
11.12.21

Risky Investment
buy
Adaptimmune Therapeutics PLC ADR

Start price
Target price
Perf. (%)
€3.28
02.12.21
-
02.12.22
-0.61%
11.12.21

Risky Investment
buy
Fate Therapeutics Inc.

Start price
Target price
Perf. (%)
€42.42
03.12.21
-
03.12.22
7.50%
11.12.21

Risky Investment
buy
Aldeyra Therapeutics Inc.

Start price
Target price
Perf. (%)
€5.90
07.12.21
-
07.12.22
4.24%
11.12.21

Risky Investment
buy
Arbutus Biopharma Corp.

Start price
Target price
Perf. (%)
€3.96
01.12.21
€6.00
01.12.22
-2.70%
11.12.21

Could be worthwhile Investment >10% per year
Innovative
Good culture
Below average Management
buy
Ardelyx Inc.

Start price
Target price
Perf. (%)
€0.99
30.11.21
€1.00
30.11.22
36.36%
11.12.21

Could be very worthwhile Investment >20% year
Good culture
Innovative
Few uniques
Krystal Biotech

Start price
Target price
Perf. (%)
€77.00
29.11.21
-
29.11.22
-19.48%
10.12.21

Probably not worthwhile Investment
buy
Forte Biosciences Inc.

Start price
Target price
Perf. (%)
€3.44
08.09.21
-
08.09.22
-34.88%
08.12.21

Could be worthwhile Investment >10% per year
Xenon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€26.00
05.10.21
-
05.10.22
-10.00%
08.12.21

Probably not worthwhile Investment
buy
Biocryst Pharmaceuticals

Start price
Target price
Perf. (%)
€5.51
07.12.20
€25.00
07.12.21
93.92%
08.12.21

Could be very worthwhile Investment >20% year
buy
Drägerwerk AG & Co. KGaA VZO

Start price
Target price
Perf. (%)
€76.10
09.07.21
-
09.07.22
-25.49%
05.12.21

Oramed Pharmaceuticals

Start price
Target price
Perf. (%)
€3.58
04.12.20
-
04.12.21
282.12%
05.12.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group
iRhythm Technologies Inc

Start price
Target price
Perf. (%)
€151.00
02.12.20
-
02.12.21
-42.05%
03.12.21

Risky Investment
Krystal Biotech

Start price
Target price
Perf. (%)
€42.60
30.10.21
€37.00
30.11.22
54.93%
01.12.21

Could be very worthwhile Investment >20% year
Abivax S.A.

Start price
Target price
Perf. (%)
€30.50
28.06.21
€25.00
28.06.22
-16.39%
01.12.21

Future proof or reliable business model
Probably not worthwhile Investment
overvalued
Very low/no dividend yield expected
Valneva SE

Start price
Target price
Perf. (%)
€11.84
13.09.21
-
13.09.22
139.19%
29.11.21

Revenue growth >5% per year expected
Could be very worthwhile Investment >20% year
High valuation
Growths slower than the competition
buy
Axonics Modulation Technologies Inc

Start price
Target price
Perf. (%)
€37.20
28.11.20
€42.00
28.11.21
31.72%
29.11.21

Could be worthwhile Investment >10% per year
buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€17.50
22.11.21
-
22.11.22
-2.83%
28.11.21

Risky Investment
Inovio Pharma

Start price
Target price
Perf. (%)
€6.92
10.07.21
€5.80
10.07.22
-6.86%
27.11.21

Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
buy
InMed Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€37.75
17.11.21
€50.00
17.11.22
4.64%
27.11.21

Could be worthwhile Investment >10% per year
Capable Management
Good culture
Little innovation
buy
Valneva SE

Start price
Target price
Perf. (%)
€21.24
15.11.21
€25.00
15.11.22
33.24%
27.11.21

Fair valuation
Very Future proof/growth oriented business model
Could be very worthwhile Investment >20% year
Higher risks for its business
Catalyst Biosciences Inc

Start price
Target price
Perf. (%)
€0.79
13.11.21
€0.000
13.11.22
-26.11%
27.11.21

Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
buy
Aurinia Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€23.97
15.11.21
-
15.11.22
-28.16%
26.11.21

Could be worthwhile Investment >10% per year
Boiron S.A.

Start price
Target price
Perf. (%)
€38.55
13.04.21
€36.00
13.04.22
-1.30%
26.11.21

Could be worthwhile Investment >10% per year